BRPI0415628A - suspensões analgésicas para liberação controlada - Google Patents

suspensões analgésicas para liberação controlada

Info

Publication number
BRPI0415628A
BRPI0415628A BRPI0415628-5A BRPI0415628A BRPI0415628A BR PI0415628 A BRPI0415628 A BR PI0415628A BR PI0415628 A BRPI0415628 A BR PI0415628A BR PI0415628 A BRPI0415628 A BR PI0415628A
Authority
BR
Brazil
Prior art keywords
controlled release
suspensions
release analgesic
analgesic suspensions
ibuprofen
Prior art date
Application number
BRPI0415628-5A
Other languages
English (en)
Inventor
David W Wynn
Gerard Mcnally
Nick Parikh
Original Assignee
Mcneil Ppc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcneil Ppc Inc filed Critical Mcneil Ppc Inc
Publication of BRPI0415628A publication Critical patent/BRPI0415628A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

"SUSPENSõES ANALGéSICAS PARA LIBERAçãO CONTROLADA". A presente invenção refere-se a um método para administrar drogas antiinflamatórias não-esteróides, em particular derivados de ácido propiónico tais como ibuprofeno, ou acetaminofeno através de uma suspensão líquida. Este método proporciona um melhor efeito terapêutico, em particular alívio da dor, durante períodos de tempo prolongados.
BRPI0415628-5A 2003-10-30 2004-10-21 suspensões analgésicas para liberação controlada BRPI0415628A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/697,546 US20050095299A1 (en) 2003-10-30 2003-10-30 Controlled release analgesic suspensions
PCT/US2004/034709 WO2005044230A2 (en) 2003-10-30 2004-10-21 Controlled release analgesic suspensions

Publications (1)

Publication Number Publication Date
BRPI0415628A true BRPI0415628A (pt) 2006-12-12

Family

ID=34550387

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415628-5A BRPI0415628A (pt) 2003-10-30 2004-10-21 suspensões analgésicas para liberação controlada

Country Status (11)

Country Link
US (1) US20050095299A1 (pt)
EP (1) EP1694297B1 (pt)
JP (1) JP2007509937A (pt)
KR (1) KR20060096492A (pt)
CN (1) CN1874754A (pt)
BR (1) BRPI0415628A (pt)
CA (1) CA2543497C (pt)
ES (1) ES2408308T3 (pt)
NO (1) NO20062450L (pt)
RU (1) RU2006118696A (pt)
WO (1) WO2005044230A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060093631A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
CA2586288A1 (en) * 2004-12-06 2006-06-15 Janssen Pharmaceutica Nv Oral suspension comprising meloxicam
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
US20080057122A1 (en) * 2006-08-31 2008-03-06 Aaipharma Inc. Acetaminophen pharmaceutical compositions
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
RU2011133020A (ru) * 2009-01-09 2013-02-20 Панацеа Биотек Лтд. Фармацевтические суспензии двойного высвобождения
US8529914B2 (en) 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
WO2012100295A1 (en) * 2011-01-27 2012-08-02 Mayne Pharma International Pty Ltd Extended release acetaminophen liquid pharmaceutical compositions
KR101561345B1 (ko) * 2013-10-17 2015-10-16 대원제약주식회사 제어방출되는 프로피온산 계열의 약제학적 조성물
FR3027802B1 (fr) * 2014-10-31 2018-03-02 Ethypharm Granules de principe actif a double masquage de gout, leur procede de preparation et comprimes orodispersibles les contenant
CN108926530A (zh) * 2018-08-17 2018-12-04 江苏科瑞达药业有限公司 一种具有高效混悬作用的对乙酰氨基酚液体制剂

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3485719A (en) * 1967-10-13 1969-12-23 Us Agriculture Continuous process for producing xanthomonas heteropolysaccharide
GB1497044A (en) * 1974-03-07 1978-01-05 Prodotti Antibiotici Spa Salts of phenyl-alkanoic acids
US4221778A (en) * 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
GB8317696D0 (en) * 1983-06-29 1983-08-03 Shell Int Research Preparing xanthomonas heteroplysaccharide
US4762709A (en) * 1983-09-16 1988-08-09 Pennwalt Corporation Liquid prolonged release pharmaceutical formulations containing ionic constituents
US4847077A (en) * 1984-07-18 1989-07-11 Pennwalt Corporation Controlled release pharmaceutical preparations
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4873231A (en) * 1986-04-08 1989-10-10 Smith Walton J Decreasing the toxicity of an ibuprofen salt
JPS6327424A (ja) * 1986-07-17 1988-02-05 Shionogi & Co Ltd 徐放性製剤およびその製造法
US4859461A (en) * 1986-07-30 1989-08-22 Fisons Corporation Coatable ion exchange resins
US4788220A (en) * 1987-07-08 1988-11-29 American Home Products Corporation (Del.) Pediatric ibuprofen compositions
US4861797A (en) * 1987-10-15 1989-08-29 Oratech Pharmaceutical Development Corporation Liquid ibuprofen compositions and methods of making them
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
DE3822095A1 (de) * 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab Neue arzneimittelformulierung sowie verfahren zu deren herstellung
US4906478A (en) * 1988-12-12 1990-03-06 Valentine Enterprises, Inc. Simethicone/calcium silicate composition
US4975465A (en) * 1989-03-28 1990-12-04 American Home Products Corporation Orally administrable ibuprofen compositions
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
NZ234143A (en) * 1989-06-28 1991-10-25 Mcneil Ppc Inc Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
US5527545A (en) * 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
US5275822A (en) * 1989-10-19 1994-01-04 Valentine Enterprises, Inc. Defoaming composition
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
CA2061520C (en) * 1991-03-27 2003-04-22 Lawrence J. Daher Delivery system for enhanced onset and increased potency
US5183829A (en) * 1991-09-27 1993-02-02 Applied Analytical Industries, Inc. Oral liquid compositions of non-steroidal anti-inflammatory drugs
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
FI941777A7 (fi) * 1993-04-16 1994-10-17 Mcneil Ppc Inc Vesipitoinen farmaseuttinen suspensio ja menetelmä sen valmistamiseksi
IT1264855B1 (it) * 1993-06-21 1996-10-17 Zambon Spa Composizioni farmaceutiche contenenti sali dell'acido s(+)-2-(4-isobutilfenil) propionico con amminoacidi basici
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
US5759579A (en) * 1996-12-05 1998-06-02 American Home Products Corporation Pharmaceutical suspension systems
EP0946145B1 (en) * 1996-12-20 2008-09-03 McNeil-PPC, Inc. Antitussive drugs delivered by ion exchange resins
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
US5885616A (en) * 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
CN1277550A (zh) * 1997-09-11 2000-12-20 尼科梅德丹麦有限公司 非甾体抗炎药物(NSAIDs)的改进释放的复合型组合物
US6197347B1 (en) * 1998-06-29 2001-03-06 Andrx Pharmaceuticals, Inc. Oral dosage for the controlled release of analgesic
US6270790B1 (en) * 1998-08-18 2001-08-07 Mxneil-Ppc, Inc. Soft, convex shaped chewable tablets having reduced friability
US6126967A (en) * 1998-09-03 2000-10-03 Ascent Pediatrics Extended release acetaminophen particles
US6254891B1 (en) * 1998-09-03 2001-07-03 Ascent Pediatrics, Inc. Extended release acetaminophen
IN191239B (pt) * 1999-06-11 2003-10-11 Ranbaxy Lab Ltd
ES2258988T3 (es) * 1999-12-22 2006-09-16 Pharmacia Corporation Composiciones de liberacion dual de un inhibidor de la ciclooxigenasa-2.
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
US7223421B2 (en) * 2000-06-30 2007-05-29 Mcneil-Ppc, Inc. Teste masked pharmaceutical particles
AU2003271024A1 (en) * 2002-09-21 2004-04-08 Jin Wang Sustained release compound of acetamidophenol and tramadol

Also Published As

Publication number Publication date
KR20060096492A (ko) 2006-09-11
WO2005044230A2 (en) 2005-05-19
US20050095299A1 (en) 2005-05-05
EP1694297A2 (en) 2006-08-30
CA2543497A1 (en) 2005-05-19
NO20062450L (no) 2006-05-30
CA2543497C (en) 2013-02-26
ES2408308T3 (es) 2013-06-20
WO2005044230A3 (en) 2005-08-18
EP1694297B1 (en) 2013-04-10
JP2007509937A (ja) 2007-04-19
RU2006118696A (ru) 2007-12-10
CN1874754A (zh) 2006-12-06

Similar Documents

Publication Publication Date Title
BRPI0415628A (pt) suspensões analgésicas para liberação controlada
ATE484494T1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
CY1115940T1 (el) Παραγωγα υποκατεστημενου φαινυλαλκανοϊκου οξεος και η χρηση τους για τη θεραπευτικη αντιμετωπιση αναπνευστικων ασθενειων
CY1117656T1 (el) Επιλογες θεραπειας για τη νοσο του fabry
TW200500067A (en) Salts of codrugs and uses related thereto
DE60129242D1 (de) Verwendung von zoledronsäure zur schmerzbehandlung
WO2004056774A3 (en) Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
CY1118179T1 (el) Φαρμακευτικη συνθεση
NO20030724L (no) Anvendelse av derivater av valproinsyreamider og 2- valproensyreamider for terapi eller prevensjon av smerte- og/eller hodepinelidelser
CY1112738T1 (el) Μια συνδυασμενη συνθεση που περιεχει ιβουπροφαινη και παρακεταμολη
DE602007008385D1 (de) Verwendung von valproinsäure zur topischen behandlung von leichter bis mittelschwerer akne vulgaris
NO20065904L (no) Terapeutiske forbindelser
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
BRPI0415630A (pt) suspensões analgésicas para liberação controlada
BR0318201A (pt) regime de dosagem de fármaco antiinflamatório não-esteroidal
DE60108130D1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
UA91136C2 (ru) Системы, фармацевтическая композиция на его основе и способ ее применения
DE60222662D1 (de) Verwendung von l-azetylcarnitin zur herstellung eines medikaments zur präventiven post-chirurgischen schmerzbehandlung
ATE418977T1 (de) Verwendung von phenylacetylderivaten zur herstellung eines arzneimittels zur behandlung der von-hippel-lindau-erkrankung
WO2003066806A3 (en) Therapeutic use of aziridino compounds
BR0312333A (pt) Terapia de combinação e agente para sua execução
ATE464042T1 (de) Verwendung von neboglamine zur behandlung von schizophrenie
ATE442848T1 (de) Isoxazolsäure-derivat zur linderung neuropathischer schmerzen
BRPI0415111A (pt) composição farmacêutica que compreende o ácido 5-metil-2-( 2`-cloro-6`-fluoroanilino) fenilacético

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/167, 9/50, 9/16; A61P 29/00

Ipc: A61K 31/167 (2011.01), A61K 9/50 (2011.01), A61K 9

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2433 DE 22-08-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.